News & Updates

RYGB in severe obesity leads to weight loss, hypertension remission
RYGB in severe obesity leads to weight loss, hypertension remission
29 Aug 2022 byRoshini Claire Anthony

In patients with severe obesity, undergoing either laparoscopic sleeve gastrectomy (LSG) or laparoscopic Roux-en-Y gastric bypass (RYGB) resulted in weight loss, according to long-term follow-up of the SLEEVEPASS* trial. However, remission of hypertension was more likely in patients who underwent RYGB compared with LSG.

RYGB in severe obesity leads to weight loss, hypertension remission
29 Aug 2022
Obese, postmenopausal women on proinflammatory diet at highest risk of breast cancer
Obese, postmenopausal women on proinflammatory diet at highest risk of breast cancer
29 Aug 2022
Gout, hyperuricaemia meds less common among diabetics on SGLT2is
Gout, hyperuricaemia meds less common among diabetics on SGLT2is
28 Aug 2022

Patients with type 2 diabetes mellitus (T2DM) taking sodium-glucose cotransporter 2 inhibitors (SGLT2is) are less likely to be prescribed antigout or antihyperuricaemic drugs, a recent study has found.

Gout, hyperuricaemia meds less common among diabetics on SGLT2is
28 Aug 2022
Dulaglutide safely controls glucose in T2D with CKD
Dulaglutide safely controls glucose in T2D with CKD
28 Aug 2022

In patients with type 2 diabetes (T2D) with chronic kidney disease (CKD), once-weekly dosage with dulaglutide achieves adequate glycaemic control along with a reduced decline in estimated glomerular filtration rate (eGFR), reports a recent study.

Dulaglutide safely controls glucose in T2D with CKD
28 Aug 2022